Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype

Jorge Rebola, Pedro Aguiar, Ana Blanca, Rodolfo Montironi, Alessia Cimadamore, Liang Cheng, Vanessa Henriques, Paula Lobato-Faria, Antonio Lopez-Beltran

Research output: Contribution to journalArticle

Abstract

Bladder cancer tumors can be divided into two molecular subtypes referred to as luminal or basal. Each subtype may react differently to current chemotherapy or immunotherapy. Likewise, the technology required for comprehensive molecular analysis is expensive and not yet applicable for routine clinical diagnostics. Therefore, it has been suggested that the immunohistochemical expressions of only two markers, luminal (CK20+, CK5/6–) and basal (CK5/6+, CK20–), is sufficient to identify the molecular subtypes of bladder cancer. This would represent a molecular grade that could be used in daily practice. Molecular classification is done using immunohistochemistry to assess luminal-basal phenotype based on tissular expression of CK20 and CK5/6 as surrogate for luminal or basal subtypes, respectively. A series of 147 non-muscle-invasive bladder carcinoma cases was selected, and the tumors were divided into four subgroups based on the presence of CK20 and/or CK5/6, that is, null (CK20−, CK5/6−), mixed (CK20+, CK5/6+), basal (CK20−, CK5/6+), and luminal (CK20+, CK5/6−) categories. Survival analysis was estimated using the Kaplan-Meier method and the log-rank test. Hazard ratios were calculated by Cox multivariate analysis. The molecular grade included cases with null (n = 89), mixed (n = 6), basal (n = 20), and luminal (n = 32) phenotypes with differences in recurrence-free, progression-free and cancer-specific survival associated with molecular-grade categories in patients with low- or high-grade Ta, or high-grade T1 tumors. The multivariate analysis identified the luminal phenotype as a predictor of more aggressive neoplasms. Our findings provide a rationale to investigate luminal and basal subtypes of bladder cancer using two gene expression signatures as surrogate markers and show that non-muscle-invasive bladder carcinoma can be stratified into biologically and clinically different subgroups by using an immunohistochemical classifier.

Original languageEnglish (US)
JournalVirchows Archiv
DOIs
StatePublished - Jan 1 2019
Externally publishedYes

Fingerprint

Urinary Bladder Neoplasms
Phenotype
Neoplasms
Urinary Bladder
Multivariate Analysis
Carcinoma
Survival Analysis
Transcriptome
Immunotherapy
Biomarkers
Immunohistochemistry
Technology
Recurrence
Drug Therapy
Survival

Keywords

  • Basal
  • Bladder cancer
  • Luminal
  • Molecular grade
  • Prognosis
  • Survival

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Biology
  • Cell Biology

Cite this

Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer : the role of molecular grade based on luminal/basal phenotype. / Rebola, Jorge; Aguiar, Pedro; Blanca, Ana; Montironi, Rodolfo; Cimadamore, Alessia; Cheng, Liang; Henriques, Vanessa; Lobato-Faria, Paula; Lopez-Beltran, Antonio.

In: Virchows Archiv, 01.01.2019.

Research output: Contribution to journalArticle

Rebola, Jorge ; Aguiar, Pedro ; Blanca, Ana ; Montironi, Rodolfo ; Cimadamore, Alessia ; Cheng, Liang ; Henriques, Vanessa ; Lobato-Faria, Paula ; Lopez-Beltran, Antonio. / Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer : the role of molecular grade based on luminal/basal phenotype. In: Virchows Archiv. 2019.
@article{79a29673088440c699109d292899cd3a,
title = "Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype",
abstract = "Bladder cancer tumors can be divided into two molecular subtypes referred to as luminal or basal. Each subtype may react differently to current chemotherapy or immunotherapy. Likewise, the technology required for comprehensive molecular analysis is expensive and not yet applicable for routine clinical diagnostics. Therefore, it has been suggested that the immunohistochemical expressions of only two markers, luminal (CK20+, CK5/6–) and basal (CK5/6+, CK20–), is sufficient to identify the molecular subtypes of bladder cancer. This would represent a molecular grade that could be used in daily practice. Molecular classification is done using immunohistochemistry to assess luminal-basal phenotype based on tissular expression of CK20 and CK5/6 as surrogate for luminal or basal subtypes, respectively. A series of 147 non-muscle-invasive bladder carcinoma cases was selected, and the tumors were divided into four subgroups based on the presence of CK20 and/or CK5/6, that is, null (CK20−, CK5/6−), mixed (CK20+, CK5/6+), basal (CK20−, CK5/6+), and luminal (CK20+, CK5/6−) categories. Survival analysis was estimated using the Kaplan-Meier method and the log-rank test. Hazard ratios were calculated by Cox multivariate analysis. The molecular grade included cases with null (n = 89), mixed (n = 6), basal (n = 20), and luminal (n = 32) phenotypes with differences in recurrence-free, progression-free and cancer-specific survival associated with molecular-grade categories in patients with low- or high-grade Ta, or high-grade T1 tumors. The multivariate analysis identified the luminal phenotype as a predictor of more aggressive neoplasms. Our findings provide a rationale to investigate luminal and basal subtypes of bladder cancer using two gene expression signatures as surrogate markers and show that non-muscle-invasive bladder carcinoma can be stratified into biologically and clinically different subgroups by using an immunohistochemical classifier.",
keywords = "Basal, Bladder cancer, Luminal, Molecular grade, Prognosis, Survival",
author = "Jorge Rebola and Pedro Aguiar and Ana Blanca and Rodolfo Montironi and Alessia Cimadamore and Liang Cheng and Vanessa Henriques and Paula Lobato-Faria and Antonio Lopez-Beltran",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s00428-019-02593-x",
language = "English (US)",
journal = "Virchows Archiv",
issn = "0945-6317",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer

T2 - the role of molecular grade based on luminal/basal phenotype

AU - Rebola, Jorge

AU - Aguiar, Pedro

AU - Blanca, Ana

AU - Montironi, Rodolfo

AU - Cimadamore, Alessia

AU - Cheng, Liang

AU - Henriques, Vanessa

AU - Lobato-Faria, Paula

AU - Lopez-Beltran, Antonio

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Bladder cancer tumors can be divided into two molecular subtypes referred to as luminal or basal. Each subtype may react differently to current chemotherapy or immunotherapy. Likewise, the technology required for comprehensive molecular analysis is expensive and not yet applicable for routine clinical diagnostics. Therefore, it has been suggested that the immunohistochemical expressions of only two markers, luminal (CK20+, CK5/6–) and basal (CK5/6+, CK20–), is sufficient to identify the molecular subtypes of bladder cancer. This would represent a molecular grade that could be used in daily practice. Molecular classification is done using immunohistochemistry to assess luminal-basal phenotype based on tissular expression of CK20 and CK5/6 as surrogate for luminal or basal subtypes, respectively. A series of 147 non-muscle-invasive bladder carcinoma cases was selected, and the tumors were divided into four subgroups based on the presence of CK20 and/or CK5/6, that is, null (CK20−, CK5/6−), mixed (CK20+, CK5/6+), basal (CK20−, CK5/6+), and luminal (CK20+, CK5/6−) categories. Survival analysis was estimated using the Kaplan-Meier method and the log-rank test. Hazard ratios were calculated by Cox multivariate analysis. The molecular grade included cases with null (n = 89), mixed (n = 6), basal (n = 20), and luminal (n = 32) phenotypes with differences in recurrence-free, progression-free and cancer-specific survival associated with molecular-grade categories in patients with low- or high-grade Ta, or high-grade T1 tumors. The multivariate analysis identified the luminal phenotype as a predictor of more aggressive neoplasms. Our findings provide a rationale to investigate luminal and basal subtypes of bladder cancer using two gene expression signatures as surrogate markers and show that non-muscle-invasive bladder carcinoma can be stratified into biologically and clinically different subgroups by using an immunohistochemical classifier.

AB - Bladder cancer tumors can be divided into two molecular subtypes referred to as luminal or basal. Each subtype may react differently to current chemotherapy or immunotherapy. Likewise, the technology required for comprehensive molecular analysis is expensive and not yet applicable for routine clinical diagnostics. Therefore, it has been suggested that the immunohistochemical expressions of only two markers, luminal (CK20+, CK5/6–) and basal (CK5/6+, CK20–), is sufficient to identify the molecular subtypes of bladder cancer. This would represent a molecular grade that could be used in daily practice. Molecular classification is done using immunohistochemistry to assess luminal-basal phenotype based on tissular expression of CK20 and CK5/6 as surrogate for luminal or basal subtypes, respectively. A series of 147 non-muscle-invasive bladder carcinoma cases was selected, and the tumors were divided into four subgroups based on the presence of CK20 and/or CK5/6, that is, null (CK20−, CK5/6−), mixed (CK20+, CK5/6+), basal (CK20−, CK5/6+), and luminal (CK20+, CK5/6−) categories. Survival analysis was estimated using the Kaplan-Meier method and the log-rank test. Hazard ratios were calculated by Cox multivariate analysis. The molecular grade included cases with null (n = 89), mixed (n = 6), basal (n = 20), and luminal (n = 32) phenotypes with differences in recurrence-free, progression-free and cancer-specific survival associated with molecular-grade categories in patients with low- or high-grade Ta, or high-grade T1 tumors. The multivariate analysis identified the luminal phenotype as a predictor of more aggressive neoplasms. Our findings provide a rationale to investigate luminal and basal subtypes of bladder cancer using two gene expression signatures as surrogate markers and show that non-muscle-invasive bladder carcinoma can be stratified into biologically and clinically different subgroups by using an immunohistochemical classifier.

KW - Basal

KW - Bladder cancer

KW - Luminal

KW - Molecular grade

KW - Prognosis

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=85068146457&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068146457&partnerID=8YFLogxK

U2 - 10.1007/s00428-019-02593-x

DO - 10.1007/s00428-019-02593-x

M3 - Article

AN - SCOPUS:85068146457

JO - Virchows Archiv

JF - Virchows Archiv

SN - 0945-6317

ER -